NACE 46.39 in FR. Official registry identity, company-size evidence and a rounded indicative valuation range on one indexed company profile.
A broad indicative range based on official company-size information and governed sector comparables. It is not a company-specific appraisal, market value, asking price, or offer.
Based on official company-size informationCreate a free account to see the detailed curve, the factors that influence it, and an indicative five-year outlook.
Free account · private workspace
This broad public range is a starting point based on governed sector or size evidence. Create a free account to refine it with verified company data and build a five-year outlook.
This company is not currently listed for sale on Upswitch.
This is an estimate, not an asking price. It is based on dated public sources and is not an owner forecast, offer, investment advice, or confirmation that the company is for sale.
Request verified control to add current figures, improve the profile and manage what happens next. We verify ownership before granting access.
Operating as a business in NACE sector 46.39, APEROLIV is registered in France. The company was founded in 2026, incorporated as a 5499.
APEROLIV is listed in French National Business Register (RNE/INPI) under registry number 105344501.
APEROLIV's registered activity maps to NACE 46.39; public financial-account availability varies by registry and company type.
APEROLIV's public range combines official company-size information with sector multiples. It remains indicative and is not a midpoint, sale price, offer, or recommendation.
The range is refreshed when the official size or registry source for APEROLIV changes.
APEROLIV was founded in 2026 and is registered with French National Business Register (RNE/INPI), incorporated as a 5499.
APEROLIV is registered under NACE 46.39: NACE 46.39. That places the business within the French cluster for this activity.
This page shows a rounded, automated indicative range generated by Upswitch from official registry facts, public company-size information, filed accounts where available, and governed sector benchmarks. The evidence basis is labelled beside the graph. It is not a certified or statutory valuation, sale price, offer, recommendation, or financial, investment, tax or legal advice. Figures for APEROLIV may be incomplete or inaccurate and must not be relied upon for any transaction; a precise valuation needs owner- or advisor-supplied data.
Company identity and public facts are reused from the official or licensed source named on this page, with its filing or update date. Upswitch estimates remain distinct from source facts and do not imply endorsement by the registry. Natural-person enterprises are excluded from public valuation pages, and public registry personal data is not used for direct marketing.
Connected to this company and want something corrected? Request a correction or removal · Privacy policy · Terms & conditions · Data sources & evidence
